Literature DB >> 8098178

The St. Hans Rating Scale for extrapyramidal syndromes: reliability and validity.

J Gerlach1, S Korsgaard, P Clemmesen, A M Lauersen, G Magelund, U Noring, U J Povlsen, P Bech, D E Casey.   

Abstract

The St. Hans Rating Scale (SHRS) is a multidimensional rating scale for the evaluation of neuroleptic-induced hyperkinesia, parkinsonism, akathisia and dystonia. This scale and the Abnormal Involuntary Movement Scale (AIMS) were tested by 7 raters (2 experienced, 2 less experienced and 3 totally inexperienced) in 30 psychiatric patients with tardive dyskinesia (TD). The test was performed 3 times in the same patients: 1) live evaluation during a video recording, 2) evaluation 2 weeks later from the videotape, and 3) evaluation after another 2 weeks from the same videotape. The intrarater reliability was high in the experienced group (0.91-0.96 for SHRS hyperkinesia scale, 0.80-0.84 for AIMS, and 0.82-0.97 for SHRS total parkinsonism). No significant changes occurred from live to video evaluation. The interrater reliability coefficient for the experienced group was also high: 0.89-0.95 for the SHRS hyperkinesia scale, 0.76-0.85 for the AIMS scale and 0.95-0.98 for the SHRS parkinsonism scale. The less experienced and the inexperienced raters had coefficients for intra- and interrater reliability that were 0.10 and 0.20 lower, respectively. The SHRS parkinsonism scale had a high construct validity, as determined by the homogeneity coefficients of Cronbach (0.82) and Loevinger (0.43). The corresponding coefficients for the hyperkinesia scales were low, in agreement with the individual distribution of TD (only about 50% present extremity dyskinesia and less than 25% facial, head and trunk dyskinesia, independent of the severity of the syndrome). Finally, convergent validity was found between the SHRS hyperkinesia scale and AIMS and divergent validity between all of the other scales.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8098178     DOI: 10.1111/j.1600-0447.1993.tb03366.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  34 in total

1.  Clozapine versus typical antipsychotics. A retro- and prospective study of extrapyramidal side effects.

Authors:  L Peacock; T Solgaard; H Lublin; J Gerlach
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

2.  Drug-induced parkinsonism.

Authors:  Frandy Susatia; Hubert H Fernandez
Journal:  Curr Treat Options Neurol       Date:  2009-05       Impact factor: 3.598

3.  Tardive dyskinesia: therapeutic options for an increasingly common disorder.

Authors:  Leslie J Cloud; Deepti Zutshi; Stewart A Factor
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

4.  A Neural Signature of Parkinsonism in Patients With Schizophrenia Spectrum Disorders: A Multimodal MRI Study Using Parallel ICA.

Authors:  Robert C Wolf; Mahmoud Rashidi; Stefan Fritze; Katharina M Kubera; Georg Northoff; Fabio Sambataro; Vince D Calhoun; Lena S Geiger; Heike Tost; Dusan Hirjak
Journal:  Schizophr Bull       Date:  2020-07-08       Impact factor: 9.306

5.  Treatment adherence in schizophrenia: a patient-level meta-analysis of combined CATIE and EUFEST studies.

Authors:  Pál Czobor; Richard A Van Dorn; Leslie Citrome; Rene S Kahn; W Wolfgang Fleischhacker; Jan Volavka
Journal:  Eur Neuropsychopharmacol       Date:  2015-04-30       Impact factor: 4.600

6.  The interplay among psychopathology, personal resources, context-related factors and real-life functioning in schizophrenia: stability in relationships after 4 years and differences in network structure between recovered and non-recovered patients.

Authors:  Silvana Galderisi; Paola Rucci; Armida Mucci; Alessandro Rossi; Paola Rocca; Alessandro Bertolino; Eugenio Aguglia; Mario Amore; Antonello Bellomo; Paola Bozzatello; Paola Bucci; Bernardo Carpiniello; Enrico Collantoni; Alessandro Cuomo; Liliana Dell'Osso; Fabio Di Fabio; Massimo di Giannantonio; Dino Gibertoni; Giulia Maria Giordano; Carlo Marchesi; Palmiero Monteleone; Lucio Oldani; Maurizio Pompili; Rita Roncone; Rodolfo Rossi; Alberto Siracusano; Antonio Vita; Patrizia Zeppegno; Mario Maj
Journal:  World Psychiatry       Date:  2020-02       Impact factor: 49.548

7.  The clinical characterization of the patient with primary psychosis aimed at personalization of management.

Authors:  Mario Maj; Jim van Os; Marc De Hert; Wolfgang Gaebel; Silvana Galderisi; Michael F Green; Sinan Guloksuz; Philip D Harvey; Peter B Jones; Dolores Malaspina; Patrick McGorry; Jouko Miettunen; Robin M Murray; Keith H Nuechterlein; Victor Peralta; Graham Thornicroft; Ruud van Winkel; Joseph Ventura
Journal:  World Psychiatry       Date:  2021-02       Impact factor: 49.548

8.  Hostility in schizophrenia: An integrated analysis of the combined Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and the European First Episode Schizophrenia Trial (EUFEST) studies.

Authors:  J Volavka; R A Van Dorn; L Citrome; R S Kahn; W W Fleischhacker; P Czobor
Journal:  Eur Psychiatry       Date:  2015-12-04       Impact factor: 5.361

9.  Transcutaneous noninvasive vagus nerve stimulation (tVNS) in the treatment of schizophrenia: a bicentric randomized controlled pilot study.

Authors:  Alkomiet Hasan; Claus Wolff-Menzler; Sebastian Pfeiffer; Peter Falkai; Elif Weidinger; Andrea Jobst; Imke Hoell; Berend Malchow; Peyman Yeganeh-Doost; Wolfgang Strube; Silke Quast; Norbert Müller; Thomas Wobrock
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2015-07-26       Impact factor: 5.270

10.  Repetitive transcranial magnetic stimulation for the treatment of negative symptoms in residual schizophrenia: rationale and design of a sham-controlled, randomized multicenter study.

Authors:  Joachim Cordes; P Falkai; B Guse; A Hasan; T Schneider-Axmann; M Arends; G Winterer; W Wölwer; E Ben Sliman; M Ramacher; C Schmidt-Kraepelin; C Ohmann; B Langguth; M Landgrebe; P Eichhammer; E Frank; J Burger; G Hajak; M Rietschel; T Wobrock
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2009-11       Impact factor: 5.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.